Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 19;11:5278. doi: 10.1038/s41467-020-19096-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Three- to 4-week-old male and female hSTAT2 KI mice were administered 200 μg of the indicated murine (a, b) or human (c, d) mAbs and inoculated subcutaneously with 10⁵ FFU of ZIKV. Viral burden was assessed at 9 dpi in the spleen (a, c) and brain (b, d). a, b Isotype control, n = 33; Z12, n = 8; Z13, n = 10; Z11, n = 10; Z15, n = 10; Z17, n = 9; Z18, n = 15; Z14, n = 10; Z16, n = 10; Z20, n = 9. c, d Isotype control, n = 27; 749-A4, n = 11; 749-A4 LALA, n = 11; ZIKV-231, n = 11; ZIKV-231 LALA, n = 11; ZIKV-292, n = 15; ZIKV-292 LALA, n = 11. Data are pooled from at least two experiments (Kruskal–Wallis one-way ANOVA with Dunn’s post-test comparison between the indicated groups; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; a Z11, p = 0.002; b Z11, p = 0.015; Z15, p = 0.006; Z17, p = 0.003; c isotype vs. 749-A4, p = 0.0001; ZIKV-231 vs. ZIKV-231 LALA, p = 0.004; d isotype vs. ZIKV-231, p = 0.039; isotype vs. ZIKV-292, p = 0.012; isotype vs. 749-A4, p = 0.013; ZIKV-231 vs. ZIKV-231 LALA, p = 0.004; ZIKV-292 vs. ZIKV-292 LALA, p = 0.003; 749-A4 vs. 749-A4 LALA, p = 0.013). Dotted lines denote the limit of detection (LOD) of the assay. e–h Four- to 5-week-old male C57BL/6J mice administered 1 mg of an anti-Ifnar1-blocking mAb and 500 μg of the indicated murine (e, f) or human (g, h) mAbs. The following day, mice were inoculated subcutaneously with ZIKV and mortality (e, g) and weights (f, h) were tracked. Data are representative of two experiments and survival analysis was performed using the Mantel–Cox log-rank test with Bonferroni correction compared to the isotype group (e isotype, n = 13; Z15, n = 14, p = 0.052; Z17, n = 14, p = 0.018; Z18, n = 14, p = 0.089; g: isotype, n = 16; ZIKV-292, n = 16, p = 0.026; 749-A4, n = 16, p < 0.002). In the figure: *p < 0.05, **p < 0.01. Weights were analyzed by two-way ANOVA with Dunnett’s post-test comparison to isotype-treated animals (*p < 0.05; f Z15: day 10, p = 0.037; Z17: day 8, p = 0.037; day 9, p = 0.009; day 10, p = 0.002; day 11, p = 0.006; h 749-A4: day 9, p = 0.014; day 10, p = 0.005; ZIKV-292: day 16, p = 0.045; day 18, p = 0.037; day 20, p = 0.027); error bars represent the mean values ± SD. Source data are provided as a Source Data file for Figs. 1f, h.